SEPT9; A PROMISING BLOOD-BASE BIOMARKER FOR EARLY DETECTION OF COLORECTAL CANCER.
Sussan Farmand-Rad, Ashraf Karbasi, Mahmood Tavallaei*, Somayeh Chavoshei, Hasan Ashoori, Ghasem Azizi Tabesh
Background: Colorectal cancer (CRC) is the fourth most frequent cancer worldwide. CRC screening could reduce cancer-related mortality. The aim of this study was evaluation of septin9 methylated DNA for detection of CRC and precancerous colorectal lesions. Methods: Plasma samples were collected from 25 untreated CRC patients, 20 polyposis adenoma and 42 healthy control subjects before colonoscopy. We used methylation-specific PCR to assay the methylation status of septin9. Results: Septin9 was hypermethylated in 64% of CRC patients and 15% of polyposis adenoma. Sensitivity and specificity of septin9 methylated DNA test was 64% (95% CI: %43-%83) and 83% (95% CI: 0/68- 0/98) respectively. Conclusion: Results of this study suggest that septin9 is a valuable biomarker for CRC screening
Keywords: septin9, colorectal cancer, methylation, screening test.
[Full Text Article]